1. Fibrin and Thrombin Sealants in Vascular and Cardiac Surgery: A Systematic Review and Meta-analysis
- Author
-
Emilie P. Belley-Côté, John Harlock, Mark Crowther, Richard P. Whitlock, Bhagwanpreet Kaur, Anser Daud, and Graham R. McClure
- Subjects
medicine.medical_specialty ,Time Factors ,Blood transfusion ,medicine.medical_treatment ,Blood Loss, Surgical ,MEDLINE ,Fibrin Tissue Adhesive ,Postoperative Hemorrhage ,030204 cardiovascular system & hematology ,030230 surgery ,Hemostatics ,Fibrin ,03 medical and health sciences ,0302 clinical medicine ,Thrombin ,Risk Factors ,Internal medicine ,medicine ,Humans ,Cardiac Surgical Procedures ,Prospective cohort study ,Hemostasis ,biology ,business.industry ,Confidence interval ,Cardiac surgery ,Treatment Outcome ,Meta-analysis ,biology.protein ,Tissue Adhesives ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Vascular Surgical Procedures ,medicine.drug - Abstract
In vascular and cardiac surgery, the ability to maintain haemostasis and seal haemorrhagic tissues is key. Fibrin and thrombin based sealants were introduced as a means to prevent or halt bleeding during surgery. Whether fibrin and thrombin sealants affect surgical outcomes is poorly established. A systematic review and meta-analysis was performed to examine the impact of fibrin or thrombin sealants on patient outcomes in vascular and cardiac surgery.Cochrane CENTRAL, Embase, and MEDLINE, as well as trial registries, conference abstracts, and reference lists of included articles were searched from inception to December 2019.Studies comparing the use of fibrin or thrombin sealant with either an active (other haemostatic methods) or standard surgical haemostatic control in vascular and cardiac surgery were searched for. The Cochrane risk of bias tool and the ROBINS-I tool (Risk Of Bias In Non-randomised Studies - of Interventions) were used to assess the risk of bias of the included randomised and non-randomised studies; quality of evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Two reviewers screened studies, assessed risk of bias, and extracted data independently and in duplicate. Data from included trials were pooled using a random effects model.Twenty-one studies (n = 7 622 patients) were included: 13 randomised controlled trials (RCTs), five retrospective, and three prospective cohort studies. Meta-analysis of the RCTs showed a statistically significant decrease in the volume of blood lost (mean difference 120.7 mL, in favour of sealant use [95% confidence interval {CI} -150.6 - -90.7; p .001], moderate quality). Time to haemostasis was also shown to be reduced in patients receiving sealant (mean difference -2.5 minutes [95% CI -4.0 - -1.1; p .001], low quality). Post-operative blood transfusions, re-operation due to bleeding, and 30 day mortality were not significantly different for either RCTs or observational data.The use of fibrin and thrombin sealants confers a statistically significant but clinically small reduction in blood loss and time to haemostasis; it does not reduce blood transfusion. These Results may support selective rather than routine use of fibrin and thrombin sealants in vascular and cardiac surgery.
- Published
- 2020